Renal Cell Carcinoma
Systemic therapy for mRCC: second line and beyond

Matilda (60 years old)

Matilda is a 60-year-old travel agent with a soft spot for northern Europe regions. She would never choose a sunny beach over fjords and northern lights!

  • Diagnosed with metastatic ccRCC with sarcomatoid features (2 lesions in the lung, 1 in liver), PD-L1 positive
  • Started ipilimumab + nivolumab combination therapy 3 years ago
  • She completed 4 cycles of ipilimumab, with a partial response to this regimen (only 1 metastatic lesion remains, in the lung). After 2 years of maintenance nivolumab, she discontinued treatment in agreement with the treating physician

Now, 1 year after stopping nivolumab, she presents with a new metastatic site in the liver.

Which treatment option would you choose for this patient?